Eli Lilly and Company’s stock price dropped after rejecting a “mini-tender” offer.
🔴 (-3.0%) short-term forecast:
🟢 (+1.1%) long-term forecast:
Stock AI’s (LLY) Forecast get (+5.4% Profit)
StockAI’s analysis delivers real-world results. On 04 March 2024, $LLY ($795.4), StockAI predicted a long-term 🔴 sell signal. It was accurate: 1 month later price dropped to $752.1 (🔴-5.4%). Selling LLY on this signal yielded a +5.4% profit 💰💰.
LLY-Eli Lilly and Company News
🟢 Eli Lilly and Company (NYSE:LLY) is set to report first-quarter earnings on Tuesday, April 30, with expectations of $8.9 billion in sales and $2.46 in adjusted earnings per share.
🔴 Eli Lilly and Company has reportedly reached a settlement agreement with a medi spa that sold counterfeit versions of its popular diabetes drug, which could impact the company’s reputation and sales.
🟢 Amazon reports earnings after closing the bell, with AI strategy in investors’ sights, which could potentially boost investor confidence in the tech sector and positively impact Eli Lilly stock.
🔴 Eli Lilly and Company has been notified of an unsolicited “mini-tender” offer by Tutanota LLC to purchase shares, which could create uncertainty and lead to a decrease in stock price.
🟢 International Assets Investment Management LLC raised its position in Eli Lilly and Company, indicating confidence in the company’s future growth prospects and potentially boosting the stock price.
🔴 Eli Lilly and Company’s share price fell 3.2% during trading on Friday, which may be a result of market fluctuations or negative news affecting investor sentiment.
Eli Lilly and Company stock has been experiencing both positive and negative news recently, with developments such as earnings reports, legal settlements, and tender offers impacting investor sentiment. While positive news like increased stake holdings and strong earnings projections may lead to a rise in stock price, negative news such as counterfeit drug controversies and share price declines could result in a decrease. Investors should closely monitor these developments to make informed decisions regarding their investments in Eli Lilly and Company.
LLY-Eli Lilly and Company Analyst Ratings
In recent analyst ratings for Eli Lilly and Company (NYSE:LLY) stock:
📈 Cantor Fitzgerald reiterated their “overweight” rating on Eli Lilly and Company stock, with a price target of $815.00.
📉 Leerink Partnrs lowered their Q1 2024 earnings per share estimates for Eli Lilly and Company stock.
📈 BMO Capital Markets raised their price target on Eli Lilly and Company stock from $900.00 to $1,001.00.
Sources:
– ETFDailyNews
– ETFDailyNews
– ETFDailyNews
Disclaimer
Investors may consider the AI predictions and news summaries as one factor in their investment decisions alongside their own research and risk tolerance.
Ready to analyze your own portfolio?
Get the same AI-powered insights for any stock you choose. It's easy!
